These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32751615)

  • 21. COVID-19-related Conjunctivitis Review: Clinical Features and Management.
    Binotti W; Hamrah P
    Ocul Immunol Inflamm; 2023 May; 31(4):778-784. PubMed ID: 35394858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations.
    Ho D; Low R; Tong L; Gupta V; Veeraraghavan A; Agrawal R
    Ocul Immunol Inflamm; 2020 Jul; 28(5):726-734. PubMed ID: 32543262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Hudecová IMJČGKMPL
    Ceska Slov Farm; 2021; 70(1):18-25. PubMed ID: 34237949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Potential of Anti-coronavirus Plant Secondary Metabolites in COVID-19 Drug Discovery as an Alternative to Repurposed Drugs: A Review.
    Alipour Z; Zarezadeh S; Ghotbi-Ravandi AA
    Planta Med; 2024 Mar; 90(3):172-203. PubMed ID: 37956978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
    Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
    Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know.
    Sun CB; Wang YY; Liu GH; Liu Z
    Front Public Health; 2020; 8():155. PubMed ID: 32391309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ocular surface, coronaviruses and COVID-19.
    Willcox MD; Walsh K; Nichols JJ; Morgan PB; Jones LW
    Clin Exp Optom; 2020 Jul; 103(4):418-424. PubMed ID: 32406140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conjunctivitis as sole symptom of COVID-19: A case report and review of literature.
    Ozturker ZK
    Eur J Ophthalmol; 2021 Mar; 31(2):NP161-NP166. PubMed ID: 32703010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses.
    Meunier T; Desmarets L; Bordage S; Bamba M; Hervouet K; Rouillé Y; François N; Decossas M; Sencio V; Trottein F; Tra Bi FH; Lambert O; Dubuisson J; Belouzard S; Sahpaz S; Séron K
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0158121. PubMed ID: 34807755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye.
    Al-Sharif E; Strianese D; AlMadhi NH; D'Aponte A; dell'Omo R; Di Benedetto R; Costagliola C
    Int Ophthalmol; 2021 Jan; 41(1):349-362. PubMed ID: 32880786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular manifestation, comorbidities, and detection of severe acute respiratory syndrome-coronavirus 2 from conjunctiva in coronavirus disease 2019: A systematic review and meta-analysis.
    Ling XC; Kang EY; Lin JY; Chen HC; Lai CC; Ma DH; Wu WC
    Taiwan J Ophthalmol; 2020; 10(3):153-166. PubMed ID: 33110745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China.
    Wu P; Duan F; Luo C; Liu Q; Qu X; Liang L; Wu K
    JAMA Ophthalmol; 2020 May; 138(5):575-578. PubMed ID: 32232433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular transmission and manifestation for coronavirus disease: a systematic review.
    Almazroa A; Alamri S; Alabdulkader B; Alkozi H; Khan A; Alghamdi W
    Int Health; 2022 Mar; 14(2):113-121. PubMed ID: 34043796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Eye on COVID-19: A Meta-analysis of Positive Conjunctival Reverse Transcriptase-Polymerase Chain Reaction and SARS-CoV-2 Conjunctivitis Prevalence.
    Sopp NM; Sharda V
    Optom Vis Sci; 2021 May; 98(5):429-436. PubMed ID: 33973912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
    Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
    Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.